JAMP-DICYCLOMINE HCL 10 MG
DICYCLOMINE HYDROCHLORIDE : 10 MG · DIN 02391619 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP-DICYCLOMINE HCL?
JAMP-DICYCLOMINE HCL 10 MG contains DICYCLOMINE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02391619, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-DICYCLOMINE HCL used for?
Treatment of functional GI tract conditions involving smooth muscle spasm (e.g., irritable bowel syndrome) and adjunctive therapy in organic GI conditions (e.g., colitis, diverticulitis, peptic ulcer).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02391619 |
|---|---|
| Brand name | JAMP-DICYCLOMINE HCL |
| Generic / active ingredient | DICYCLOMINE HYDROCHLORIDE : 10 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | A03AA07 DICYCLOVERINE |
| AHFS class | 12:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Oct-2012 |
| Original market date | 2012-10-23 00:00:00 |
How is it administered?
Adults: 10-20 mg 3-4 times daily. May increase to 160 mg/day. Discontinue if efficacy not achieved in 2 weeks or if side effects limit dose to <80 mg/day. Tablets must not be split.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15 to 30°C) in a dry place. Protect from excessive heat and moisture.
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity; infants <6 months; breastfeeding; obstructive uropathy/GI disease; paralytic ileus; severe ulcerative colitis; myasthenia gravis; reflux esophagitis; glaucoma; acute hemorrhage.
Warnings and precautions
May cause drowsiness or blurred vision; avoid hazardous tasks. Psychosis/delirium reported in sensitive individuals. Diarrhea may signal incomplete intestinal obstruction.
What can be used instead?
Other Canadian products sharing ATC code A03AA07 DICYCLOVERINE. 3 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-DICYCLOMINE HCL | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02366088 |
| RIVA-DICYCLOMINE | 10 MG | CAPSULE | LABORATOIRE RIVA INC. | MARKETED | DIN 00557102 |
| BENTYLOL | 10 MG / 5 ML | SYRUP | APTALIS PHARMA CANADA ULC | CANCELLED POST MARKET | DIN 02102978 |
| BENTYLOL DOSPAN 30MG | 30 MG | TABLET (EXTENDED-RELEASE) | MERRELL PHARMS INC., DIVISION OF MERRELL DOW (CAN) | CANCELLED POST MARKET | DIN 00218723 |
| BENTYLOL INJ 10MG/ML | 10 MG | LIQUID | MERRELL PHARMS INC., DIVISION OF MERRELL DOW (CAN) | CANCELLED POST MARKET | DIN 00133965 |
| BENTYLOL TABLET 10MG | 10 MG | TABLET | APTALIS PHARMA CANADA ULC | CANCELLED POST MARKET | DIN 02103087 |
| BENTYLOL TABLET 20MG | 20 MG | TABLET | APTALIS PHARMA CANADA ULC | CANCELLED POST MARKET | DIN 02103095 |
| DICYCLOMINE CAP 10MG | 10 MG | CAPSULE | DUCHESNAY INC | CANCELLED POST MARKET | DIN 00431028 |
| DICYCLOMINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 00392812 |
| DICYCLOMINE HYDROCHLORIDE USP | 10 MG | CAPSULE | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 00392820 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.